

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

Om nucleic - nucleic search, using sw model

Run on: September 17, 2003, 16:20:15 ; Search time 285.676 seconds
(without alignments)
13909.353 Million cell updates/sec

Title: US-10-026-106B-9

Perfect score: 1472

Sequence: 1 aaggccatggcgccggccga.....acatccaccaatcgatg 1472

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 252756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Maximum Match 0%
Listing first 45 summaries

Maximum Match 100%
Listing first 45 summaries

Database : N_Genesed_19jan03,*

1: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1980.DAT:*

2: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1981.DAT:*

3: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1982.DAT:*

4: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1983.DAT:*

5: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1984.DAT:*

6: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1985.DAT:*

7: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1986.DAT:*

8: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1987.DAT:*

9: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1988.DAT:*

10: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1989.DAT:*

11: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1990.DAT:*

12: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1991.DAT:*

13: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1993.DAT:*

14: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1994.DAT:*

15: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1995.DAT:*

16: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1996.DAT:*

17: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1997.DAT:*

18: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1998.DAT:*

19: /SIDS1/gcdata/geneseq/geneseq-emb1/NA1999.DAT:*

20: /SIDS1/gcdata/geneseq/geneseq-emb1/NA2000.DAT:*

21: /SIDS1/gcdata/geneseq/geneseq-emb1/NA2001A.DAT:*

22: /SIDS1/gcdata/geneseq/geneseq-emb1/NA2001B.DAT:*

23: /SIDS1/gcdata/geneseq/geneseq-emb1/NA2002A.DAT:*

24: /SIDS1/gcdata/geneseq/geneseq-emb1/NA2003.DAT:*

Pred: No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1278	86.8	1563	24 ABQ73078	Human zcytor19 enc
2	1278	86.8	1563	25 ABQ50487	Human zcytor19 rec
3	1259	85.5	1476	24 ABQ50485	Human zcytor1 rec
4	1259	85.5	1476	25 ABQ50485	Human zcytor1 deg
5	861.8	58.5	1473	24 ABQ73069	Human zcytor1 deg
6	852.6	57.9	1560	24 ABQ73085	Zcytor19 and Fc4 f
7	612.8	41.6	1522	24 ABQ73089	MFP and zcytor19 f
8	611.6	41.5	1522	24 ABQ73089	

ALIGNMENTS

RESULT 1

ID ABQ73078
ID ABQ73078 standard; cDNA; 1563 BP.

XX ABQ73078;

XX DT 25-SB-2002 (first entry)

XX DE Human zcytor19 encoding cDNA SEQ ID NO:18.

XX KW Human; zcytor19; cytokine receptor; immuno-suppressive; cytostatic;

KW antidiabetic; antiarrhythmic; neuroprotective; antiinflammatory;

KW vaccine; immune system; T-cell specific leukaemia; lymphoma; lupus;

KW autoimmune disease; rheumatoid arthritis; multiple sclerosis; HIV;

KW diabetes mellitus; inflammatory bowel disease; Crohn's disease; asthma;

KW immunologic renal disease; glomerulonephritis; vasculitis; polyarteritis;

KW mesangioproliferative disease; chronic lymphocytic leukaemia; bone marrow; multiple myeloma;

KW secondary glomerulonephritis; scleroderma; amyloidosis; multiple myeloma;

KW haemolytic uraemic syndrome; renal neoplasm; urological neoplasm;

KW emphysema; chronic airway disease; chromosome 1; chromosome 1p36.11;

KW gene; ss.

XX OS Homo sapiens.

XX PH Key

XX CDS

1..1533 Location/Qualifiers

/*tag a

/product= "zcytor19"

/product= "zcytor19"

1..60 /*tag b

FT	mat_peptide	61..1560	Db	301
PT	/tag" c	"mature zcytor19"	Qy	367
PT	/product:		Db	361
XX	WO200244209-A2.		Qy	427
PN			Db	421
XX	06-JUN-2002.		Qy	487
PD			Db	481
XX	28-NOV-2001; 2001US-25356P.		Qy	547
PR	07-FBB-2001; 2001US-267211P.		Db	541
XX	(ZYMO) ZYMOGENETICS INC.		Qy	547
PA			Db	541
XX	XX		Qy	607
PT	Presnell SR, Xu W, Novak JE, Whitmore TB, Grant RJ;		Db	601
XX	WPI: 2001-52770/56.		Qy	667
DR	PT-PDB, ABB1643.		Db	661
XX	XX		Qy	676
CC	Novel zcytor19 polypeptides and polynucleotides useful for stimulating		Db	721
CC	immune responses in animals for producing antibodies, and for treating		Qy	676
PT	autoimmune diseases, leukemia and asthma.		Db	676
XX	PS	Claim 2; Page 174-177; 200pp; English.		675
XX	The present invention describes an isolated human zcytor19 protein (I),		Db	720
CC	anti-diabetic, antiarthritic, neuroprotective, antiinflammatory,		Qy	676
CC	anti-diabetic, nephrotoxic, dermatological, anti-HIV and haemotoxic		Db	721
CC	activities, and can be used in vaccines. (I) or an antibody binding (I)		Qy	676
CC	can be used for suppressing the immune system for reducing rejection of		Db	721
CC	tissue or organ transplants and grafts and for treating T-cell specific		Qy	676
CC	leukemias or lymphomas and autoimmune diseases including rheumatoid		Db	721
CC	arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel		Qy	676
CC	disease and Crohn's disease. The antibodies can also be used for treating		Db	721
CC	immunologic renal diseases, glomerulonephritis, mesangioliferative		Qy	676
CC	diseases, chronic lymphocytic leukemia, secondary glomerulonephritis or		Db	721
CC	vasculitis associated with lupus, polyarteritis, scleroderma, HIV-related		Qy	676
CC	diseases, amyloidosis and haemolytic uraemic syndrome. (I) and the		Db	721
CC	multiple myelomas, asthma, bronchitis, emphysema and other chronic		Qy	676
CC	airway diseases. Human zcytor19 is located to chromosome 1, more		Db	721
CC	specifically to chromosome 1p16.11. The present sequence encodes a human		Qy	676
CC	zcytor19 protein from the present invention.		Db	721
XX	XX		Qy	676
SQ	Sequence 1563 BP; 335 A; 468 C; 471 G; 289 T; 0 other;		Db	721
Query	Match	86.8%; Score 1278; DB 24; Length 1563;	Qy	676
Query	Best Local Similarity	91.4%; Pred. No. 0;	Db	721
Query	Matches	1432; Conservative 0; Mismatches 0; Indels 134; Gaps 2;	Qy	676
Db	7	ATCGCGGGCCGGAGCCGCTGGGGCCCGCTCTGCGCTCTGCGCCAGCGGCCGCGCCAGG 66	Qy	956
Db	1	ATGGCGGACCCGAGCTCTGGGGCCCTCTCTGCGCTCTGCGCCAGCGGCCAGG 60	Db	101
Qy	67	AGGCCCGCTCGCCCTCCAGATGCTGACCTGCTCCAGACTTCAGCTGTC 126	Qy	1016
Db	61	AGGCCCGCTCGCCCTCCAGATGCTGACCTGCTCCAGACTTCAGCTGTC 120	Db	1138
Qy	127	CTGACATGCTCCAGCTGGCTTGCAACCCAGATGACCTATTTCGGCTATCG 186	Qy	1198
Db	121	CTGACATGCTCCAGCTGGCTTGCAACCCAGATGACCTATTTCGGCTATCG 180	Db	1198
Qy	187	AGCTCTCCACCGTGAACGCTGGCGAGTGAAGTGTGGCGCGAACGAGGT 246	Qy	1198
Db	181	AGCTCTCCACCGTGAACGCTGGCGAGTGAAGTGTGGCGCGAACGAGGT 240	Db	1198
Qy	247	CTATGCTCTATGCTGCTGAGAACGAGCTGCTGAGAACAGCTGAGAGCTG 306	Qy	1196
Db	241	CTATGCTCTATGCTGCTGAGAACGAGCTGCTGAGAACAGCTGAGAGCTG 300	Db	1196
Qy	307	CGAGCGGTTCTCCACCTCAAGCCCTGGTGGTGGTGGTACCTGAGTACCT 366	Qy	1196

RESULT 8

ABQ73089
ID ABQ73089 standard; cDNA: 1922 BP.
XX
AC :ABQ73089;
XX
DT 25-SEP-2002 (first entry)
XX
DE MBP and zcytor19 fusion protein encoding cDNA SEQ ID NO.32.
XX
KW Human; zcytor19; cytokine receptor; immunosuppressive; cytostatic; anti-inflammatory; antidiabetic; nephroprotective; anti-inflammation; anti-HIV; haemostatic; autoimmune disease; rheumatoid arthritis; multiple sclerosis; HIV; diabetes mellitus; inflammatory bowel disease; Crohn's disease; asthma; immunological renal disease; glomerulonephritis; vasculitis; polyarteritis; mesangioproliferative disease; chronic lymphocytic leukaemia; bronchitis; secondary glomerulonephritis; scleroderma; amyloidosis; multiple myeloma; haemolytic uraemic syndrome; renal neoplasm; urological neoplasm; embryo; chronic airway disease; chromosome 1; chromosome 1p36.11; gene; ss.
XX
OS Homo sapiens.
XX
FH Synthetic.
XX
FT Key
FT CDS
FT location/Qualifiers
FT 123..1922
FT /*tag a
FT /product= "maltose binding protein" (MBP) and human
FT zcytor19 fusion protein" (MBP) and human
PN WO200244209-A2.
XX
PD 06-JUN-2002.
XX
PP 28-NOV-2001; 2001WO-US44808.
XX
PR 28-NOV-2000; 2000US-253561P.
XX
PR 07-FEB-2001; 2001US-267211P.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Preneell SR, Xu W, Novak JE, Whitmore TB, Grant RJ;
XX
PR WPI; 2002-5277056.
XX
DR P-PSDB; ABB81646.
XX
PT Novel Zcytor19 polypeptides and polynucleotides useful for stimulating autoimmune diseases, leukemia and asthma -
XX
PS Example 10; Page 189-193; 200pp; English.

The present invention describes an isolated human zcytor19 protein (I), and truncated zcytor19 proteins. (I) has immunosuppressive, cytostatic, anti-inflammatory, antiarthritic, neuroprotective, anti-HIV and haemostatic activities, and can be used in vaccines. (I) or an antibody binding (I) can be used for suppressing the immune system for reducing rejection of tissue or organ transplants and grafts and for treating T-cell specific leukemias or lymphomas and autoimmune diseases including rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel disease and Crohn's disease. The antibodies can also be used for treating

RESULT 9

ABQ73079
ID ABQ73079 standard; cDNA: 673 BP.
XX
AC ABQ73079;
XX
DT 25-SEP-2002 (first entry)
XX
DB Human truncated soluble zcytor19 encoding cDNA SEQ ID NO:20.
XX
CC Human; zcytor19; cytokine receptor; immunosuppressive; cytostatic;

immunologic renal diseases; glomerulonephritis; mesangioproliferative disease; chronic lymphocytic leukaemia; secondary glomerulonephritis or vasculitis associated with lupus, polyarteritis, scleroderma, HIV-related diseases, amyloidosis and haemolytic uraemic syndrome. (I) and the antibodies can also be used for renal or urological neoplasms and multiple myelomas, asthma, bronchitis, emphysema and other chronic airway diseases. Human zcytor19 is located to chromosome 1, more specifically to chromosome 1p36.11. The present sequence encodes a maltose binding protein (MBP) and human zcytor19 fusion protein from the present invention.

Sequence 1922 BP; 503 A; 517 C; 503 G; 399 T; 0 other;

Query Match 41.5%; Score 611.6; DB 24; Length 1922; Best Local Similarity 97.0%; Pred. No. 1.4e-149; Matches 623; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 46 CTCGCTGCGCCGCTCCAGGAGGAGCCGCGTGCCTCCAGATGAGCTGTC 105
Db 1266 CGCTCTGGCGGCTGATCCAGGCGCCGCTGCCTCCAGATGAGCTGTC 1325
QY 106 TCCGAGACTTCAGCTTACCTGACATGCTCCAGGCTGGACCCAGATG 165
Db 1326 TCCGAGACTTCAGCTTACCTGACATGCTCCAGGCTGGACCCAGATG 1385
QY 166 ACTATTGTTGCTCTACAGGCTTCACCGTACGAGCTGGAGCTGGAGAG 225
Db 1386 ACTATTGTTGCTCTACAGGCTTCACCGTACGAGCTGGAGCTGGAGAG 1445
QY 226 TGTGGGGGACGAGGAGCTCTATTTTATGCGTGAAGAACGGCTGTC 285
Db 1446 TGTGGGGGACGAGGAGCTCTATTTTATGCGTGAAGAACGGCTGTC 1505
QY 286 AACAGTCTAGGAGCAGGCTGGAGGGTCTCCAGGCTCCAGGCTCTGGAG 345
Db 1506 AACAGTCTAGGAGCAGGCTGGAGGGTCTCCAGGCTCCAGGCTCTGGAG 1565
QY 346 TCCGATATCTGTTTGTACTTCTTGTAGTGGAGACGGCCCTCCAC 405
Db 1566 TCCGATATCTGTTTGTACTTCTTGTAGTGGAGACGGCCCTCCAC 1625
QY 406 CAGACGAGGAGATCTCTAGGCCATGCACTACCGCTGGCCCTGCA 465
Db 1626 CAGACGAGGAGATCTCTAGGCCATGCACTACCGCTGGCCCTGCA 1685
QY 466 CTGATCTGAGATGATGAGCTGGAGCTTCAGAGGAGGGGGGGAAACAGACCTATT 525
Db 1686 CTGATCTGAGATGAGCTGGAGCTTCAGAGGAGGGGGGGAAACAGACCTATT 1745
QY 526 CCAGTCTCTCCATGCCACCATGCTGAGCTTCAGAGGAGGGGGGGAAACAGACCTATT 585
Db 1746 CCAGTCTCTCCATGCCACCATGCTGAGCTTCAGAGGAGGGGGGGAAACAGAC 1805
QY 585 CACTGCCTCTAGGCCAGACCATGCTGAGCTTCAGAGGAGCTTCAG 645
Db 1806 CACTGCCTCTAGGCCAGACCATGCTGAGCTTCAGAGGAGCTTCAG 1865
QY 646 AAGCCACTCTCTGCTGAGGCTCCAGGAGCTTCAG 687
Db 1866 AAGCCACTCTCTGCTGAGGCTCCAGGAGCTTCAG 1907

kw anti-rheumatic; antiarthritic; neuroprotective; antiinflammatory;
 kw antidiabetic; nephrotoxic; dermatological; anti-HIV; haemostatic;
 vaccine; immune system; T-cell specific leukaemia; lymphoma; lupus;
 autoimmune disease; rheumatoid arthritis; multiple sclerosis; HIV;
 kw diabetes mellitus; inflammatory bowel disease; Crohn's disease; asthma;
 immunologic renal disease; glomerulonephritis; vasculitis; polyarteritis;
 kw secondary glomerulonephritis; chronic lymphocytic leukaemia; bronchitis;
 haemolytic uraemic syndrome; renal neoplasia; amyloidosis; multiple myeloma;
 kw emphysema; chronic airway disease; chromosome 1; chromosome 1p36.11;
 kw gene; ss.

xx

os Homo sapiens.

fh key

ft location/Qualifiers

1..636

/*tag= a

/product= "truncated soluble zcytor19"

1..60

/*tag= b

61..633

/*tag= c

/product= "mature truncated soluble zcytor19"

28-NOV-2001; 2001WO-US44808.

PN WO200244209-A2.

XX 06-JUN-2002.

PR 28-NOV-2000; 2000US-553561P.

PR 07-FEB-2001; 2001US-267211P.

XX PA (ZYMO) ZYMOGENETICS INC.

XX PI Presnell SR, Xu W, Novak JE, Whitmore TE, Grant PJ;

XX DR WPI; 2002-527700/56.

DR P-PSDB; ABB81644.

XX PT Novel zcytor19 polypeptides and polynucleotides useful for stimulating immune responses in animals for producing antibodies, and for treating autoimmune diseases, leukemia and asthma -

XX PS Claim 2; Page 179-181; 200pp; English.

XX The present invention describes an isolated human zcytor19 protein (I), and truncated zcytor19 protein. (I) has immunosuppressive, cytostatic, antirheumatic, antiarthritic, neuroprotective, antiinflammatory, antidiabetic, nephrotoxic, dermatological, anti-HIV and haemostatic activities, and can be used in vaccines. (I) or an antibody binding (I) can be used for suppressing the immune system for reducing rejection of tissue or organ transplants and grafts and for treating T-cell specific leukaemias or lymphomas and autoimmune diseases including rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel disease and Crohn's disease. The antibodies can also be used for treating immunologic renal diseases, glomerulonephritis, mesangioproliferative disease, chronic lymphocytic leukaemia, secondary glomerulonephritis or vasculitis associated with lupus, polyarteritis, scleroderma, HIV-related antibodies can also be used for renal or urological neoplasia and multiple myeloma, asthma, bronchitis, emphysema and other chronic airway diseases. Human zcytor19 is located to chromosome 1, more specifically to chromosome 1p36.11. The present sequence encodes a human truncated soluble zcytor19 protein from the present invention.

SQ Sequence 673 BP; 127 A; 223 C; 182 G; 141 T; 0 other;

Query Match 34.6%; Score 510; DB 24; Length 673;

Best Local Similarity 100.0%; Preq. No. 3.3e-123;

Matches 510; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

PR 7 ATGGCGGGCCGAGGCTGCGGCCCTGCTCTGGCGCGCGCGCTGGCG 66

Db 1 ATGGCGGGCCGAGGCTGCGGCCCTGCTCTGGCGCGCGCGCTGGCG 60

Qy 67 AGGCCGCTGCGCCCTCCGAGATGCGCTGCTCCGAGACTCGAGTGAC 126

Db 61 AGGCCGCTGCGCCCTCCGAGACTCGAGTGACCTGCTCCGAGACTCGAGTGAC 120

Qy 127 CTGACATGCTCCAGGCTTGAGGAGTGGACCTTGACCTATTTGGCTTATCG 186

Db 121 CTGACATGCTCCAGGCTTGAGGAGTGGACCTTGACCTATTTGGCTTATCG 180

Qy 187 AGCTCTCCACCGTAGCGGTGGCGGAGTGAGTGCGGAGACAGGCTG 246

Db 181 AGCTCTCCACCGTAGCGGTGGCGGAGACAGGCTG 240

Qy 247 CTATGTTCTAGTGCTGAGGAGTGGACCTTGACACAGTCAGGAGCTG 306

Db 241 CTATGTTCTAGTGCTGAGGAGTGGACCTTGACACAGTCAGGAGCTG 300

Qy 307 CGACGGTTCTGCCAGTGCCAGTGCCCTGGTGGAGTGGACCTTGCT 366

Db 301 CGACGGTTCTGCCAGTGCCAGTGCCCTGGTGGAGTGGACCTTGCT 360

Qy 367 TTGAGTGGAGGCGCCACCTTGCTGGTGGAGTGGACCTTGCT 426

Db 361 TTGAGTGGAGGCGCCACCTTGCTGGTGGAGTGGACCTTGCT 420

Qy 427 GCGATGCGACGACCGCTGCCCTGCTGATGCCCACTGGTGGAGTGGCT 486

Db 421 GCGATGCGACGACCGCTGCCCTGCTGATGCCCACTGGTGGAGTGGCT 480

Qy 487 GCAATCTGCGAGGAGGAGGAGGAGAACAG 516

Db 481 GCAATCTGCGAGGAGGAGGAGGAGAACAG 510

RESULT 10

AD50488

ID AD50488 standard; cDNA; 674 BP.

XX

PT 24-MAR-2003 (first entry)

XX AC AD50488;

XX DB Human zcytor19 truncated soluble receptor cDNA.

XX Human; leukaemia; carcinoma; acquired immune deficiency syndrome; AIDS; melanoma; Kaposi's sarcoma; multiple myeloma; non-Hodgkin's lymphoma; hepatitis; infection; myocarditis; blood vessel formation; gene therapy; growth regulation; developmental process; immunotherapy; zcytor19; gene; receptor; ss.

XX OS Homo sapiens.

fh key

ft location/Qualifiers

1..636

/*tag= a

/product= "Human zcytor19 truncated soluble receptor"

1..60

/*tag= b

61..633

/*tag= c

/product= "Mature human zcytor19 truncated soluble receptor"

PN WO200286087-A2.

XX 31-OCT-2002.

XX PR 19-APR-2002; 2002WO-US12887.

XX PR 20-APR-2001; 2001US-885489P.

XX PR 20-APR-2001; 2001US-285424P.

QY	127	CTGACATGCTCCAGGGCTTGCAACCCAGGATGACCAATTGCGCTATCAG	186
Db	121	CTGACATGCTCCAGGGCTTGCAACCCAGGATGACCAATTGCGCTATCAG	180
QY	187	AGCTCTCCACCGTGAAGCTGGGGGAGTGGAGAGTGGTGGGGAAACAGAGTG	246
Db	181	AGCTCTCCACCGTGAAGCTGGGGGAGTGGAGAGTGGTGGGGAAACAGAGTG	240
QY	247	CTATGTTATGATGCTGAAGAAAGGAGCTGACAGAAGTGGAGCTGGCGCT	300
Db	241	CTATGTTATGATGCTGAAGAAAGGAGCTGACAGAAGTGGAGCTGGCGCT	300
QY	307	GGAGCGTTCCTCCAGCTGCTCCAGCTGAGTGGTGGGGGGCGCTGAGGCGT	306
Db	301	GGAGCGTTCCTCCAGCTGCTCCAGCTGAGTGGTGGGGGGCGCTGAGGCGT	306
QY	367	TTGAACTGGAGCCGCCACCTCTCTGGTCTACCCAGAGGGAGATCTGTAG	366
Db	361	TTGAACTGGAGCCGCCACCTCTCTGGTCTACCCAGAGGGAGATCTGTAG	420
QY	427	GCCTATGCCACCTACCGCTCCCTCTCATCCCTCACTGATCTGAGTGTAGG	486
Db	421	GCCTATGCCACCTACCGCTCCCTCTCATCCCTCACTGATCTGAGTGTAGG	480
QY	487	GCATCTGAGGAGGGGGCGGAAACAG 516	
Db	481	GCATCTGAGGAGGGGGCGGAAACAG 510	
RESULT 12			
DB	ABQ73086		
ID	ABQ73086	standard; cDNA; 633 BP.	
XX			
AC	ABQ73086;		
XX			
DT	25-SEP-2002	(first entry)	
XX			
DB	Human zcytora19 degenerate nucleotide sequence SEQ ID NO:29.		
XX			
KW	Human; zcytora19; cytokine receptor; immunosuppressive; cytopstatic; anti-diabetic; antiarthritic; neuroprotective; antiinflammatory; antidiabetic; nephrotoprotic; dermatoprotective; anti-HIV; haemostatic; vaccine; immune system; T-cell specific leukaemia; lymphoma; lupus; autoimmune disease; rheumatoid arthritis; multiple sclerosis; HIV; autoimmune disease; inflammatory bowel disease; Crohn's disease; asthma; diabetes mellitus; immunologic renal disease; glomerulonephritis; vasculitis; polyarteritis; immunoproliferative disease; chronic lymphocytic leukaemia; bronchitis; secondary glomerulonephritis; scleroderma; amyloidosis; multiple myeloma; haemolytic uraemic syndrome; renal neoplasm; urological neoplasm; embryo; chronic airway disease; chromosome 1; chromosome 1p36.11; gene; ss.		
OS	Homo sapiens;		
XX			
PN	WO200244209-A2.		
XX			
PD	06-JUN-2002.		
XX			
PP	28-NOV-2001; 2001WO-US44808.		
XX			
PR	28-NOV-2000; 2000US-253561P.		
PR	07-FBB-2001; 2001US-267211P.		
PA	(ZM0) ZIMOGENTICS INC.		
XX			
PI	Presnell SR, Xu W, Novak VB, Whitmore TB, Grant PJ;		
XX			
DR	WPI; 2002-527700/56.		
XX			
PT	Novel zcytora19 polypeptides and polynucleotides useful for stimulating immune responses in animals for producing antibodies, and for treating autoimmune diseases, leukemia and asthma		

QY	511	AAACAGACCTATTCCAGCACTCCGCCATGGCCAGCCAGCAAGAATCTCTCCAGCCAA	570
Db	207	AAACAGACCTATTCCAGCACTCCGCCATGGCCAGCCAGCAAGAATCTCTCCAGCCAA	148
QY	571	GTCGCCCGGAGCACCTCTCTCTCTGAGGACCTTCTACAGCTACTGTCCGAA	630
Db	147	GTCGCCCGGAGCACCTCTCTCTGAGGACCTTCTACAGCTACTGTCCGAA	88
QY	631	TACAGCAGTTCTAGCCACCTGCTCTGCTGGGGTCCAGG	677
Db	87	TACAGCAGTTCTAGCCACCTGCTCTGCTGGGGTCCAGG	41

AAFP5522.C
ID AAF65522 standard; cDNA; 382 BP.
XX DT
XX DB
XX AC
XX AAF65522;
XX
XX Novel human polynucleotide, SEQ ID NO: 1278.
XX Human; cytostatic; gene therapy; colon cancer; prostate cancer;
XX breast cancer; lung cancer; cancer detection; ss.
XX Homo sapiens.
XX WO200102568-A2.
XX
XX 11-JAN-2001.
XX
XX 30-JUN-2000; 2000WO-US18374.
XX
PR 02-JUL-1999; 99US-0142310.
PR 02-JUL-1999; 99US-0142311.
XX
(CHIR) CHIRON CORP.
PA (HYSQ-) HYSQ INC.
XX
PI Williams LT, Escobedo J, Innis MA, Garcia PD, Klinger J, Kassam N;
PI Reinhard C, Randazzo P, Kennedy GC, Pott D, Lamson G, Brmanac R;
PI Crkvenjakov R, Dumanac S, Dickson M, Labat I, Leshkowitz D;
PI Kita D, Garcia V, Jones LM, Srivache-Crain B;
XX DR
WPI; 2001-091805/10.
XX
PT Library of polynucleotides for diagnosing a cancerous state of a
PT mammalian cell and detecting cancer, particularly of the colon or
PT prostate, comprises 3351 human polynucleotide sequences -
XX
PS Claim 9; Page 727; 1046pp; English.
XX
CC The present sequence is one of 3351 sequences in a library of human
CC polynucleotides. The library is used to detect differentially expressed
CC genes correlated with a cancerous state of a mammalian cell and can
CC detect colon, prostate, and lung cancer. The library can be used
CC to produce probes for detection of mRNA and to produce additional copies
CC of the polynucleotides. The probes can be used for chromosome mapping or
CC the polynucleotide and for detection of transcription levels. Ribozymes
CC or antisense oligonucleotides can be generated. The polynucleotides and/or
CC their gene products are used as genetic or biochemical markers (e.g. in
CC blood or tissues) that will detect the earliest changes along the
CC carcinogenesis pathway and/or monitor the efficacy of therapies and
CC preventive interventions. The polynucleotides, polypeptides and
CC antibodies against them can be used in pharmaceutical compositions to
CC treat the cancers and proliferative disorders such as neoplasia,
CC dysplasia and hyperplasia.
XX
SQ Sequence 382 BP; 77 A; 77 C; 130 G; 98 T; 0 other;

Query Match 11.0%; Score 162.2; DB 22; Length 382;